NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling

Phio Pharmaceuticals shares rose 9.8% to $1.23 premarket after reporting no serious adverse events and strong response rates in a Phase 1b skin cancer study of PH-762. Six of seven patients at the highest dose showed a pathological response. The company plans an FDA submission in Q2 2026. The stock gained 24.4% Tuesday.

11 February 2026

NASDAQ:PHIO·Pharmaceuticals·Stock Market

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.

3 November 2025

Biotechnology·NASDAQ:PHIO·Stock Market

NASDAQ:PHIO 3 November 2025 - 11 February 2026

Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Latest article

ASX 200 hits record close after strong week — what to watch next in Australian stocks

TSX logs best month since 2020, then slips Friday: what Toronto Stock Exchange investors watch next week

Shenzhen stocks finish the week higher — but ChiNext slides as Beijing policy week looms

Nifty slips below 25,200 to end week down 1.5% on NSE; GDP reset, PMIs in focus

Popular

Adobe stock price steadies after-hours after Firefly Foundry Hollywood push; ADBE eyes March earnings